<table class="drug-table data-table table table-condensed table-bordered"><tbody><tr id="identification"><th class="divider" colspan="2">Identification</th></tr><tr><th>Name</th><td><strong>Thalidomide</strong></td></tr><tr><th>Accession Number</th><td><strong>DB01041</strong>&#160; (APRD01251)</td></tr><tr><th>Type</th><td>small molecule</td></tr><tr><th>Groups</th><td>approved, investigational, withdrawn</td></tr><tr><th>Description</th><td><p>A piperidinyl isoindole originally introduced as a non-barbiturate hypnotic, but withdrawn from the market due to teratogenic effects. It has been reintroduced and used for a number of immunological and inflammatory disorders. Thalidomide displays immunosuppresive and anti-angiogenic activity. It inhibits release of tumor necrosis factor-alpha from monocytes, and modulates other cytokine action. [PubChem]</p></td></tr><tr><th>Structure</th><td><div class="structure"><a class="moldbi-thumbnail" href="http://structures.wishartlab.com/molecules/DB01041/image.png"><img alt="Thumb" src="http://structures.wishartlab.com/molecules/DB01041/thumb.png"></a></div><div class="structure-links"><div class="btn-group btn-group-xs"><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01041.mol">MOL</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01041.sdf">SDF</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01041.pdb">PDB</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01041.smiles">SMILES</a><a class="btn btn-default" href="/structures/structures/small_molecule_drugs/DB01041.inchi">InChI</a><a class="btn btn-info" href="/structures/structures/small_molecule_drugs/DB01041">View Structure</a></div></div></td></tr><tr><th>Synonyms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="synonyms"><thead><th>Synonym</th><th>Language</th><th>Code</th></thead><tbody><tr><td>(&#177;)-N-(2,6-dioxo-3-piperidyl)phthalimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>(&#177;)-thalidomide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>1,3-dioxo-2-(2,6-dioxopiperidin-3-yl)isoindoline</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>2,6-dioxo-3-phthalimidopiperidine</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-(2,6-dioxo-3-piperidyl)phthalimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-Phthaloylglutamimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>N-Phthalylglutamic acid imide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Pro-ban M</td><td><span class="wishart wishart-not-available">Not Available</span></td><td>BAN</td></tr><tr><td>&#945;-(N-phthalimido)glutarimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>&#945;-N-phthalylglutaramide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>&#945;-phthalimidoglutarimide</td><td><span class="wishart wishart-not-available">Not Available</span></td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Salts</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Brand names</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="brands"><thead><tr><th>Name</th><th>Company</th></tr></thead><tbody><tr><td>Contergan</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Distaval</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>K-17</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Sedalis</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Softenon</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Talimol</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Thaled</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><td>Thalomid</td><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table></td></tr><tr><th>Brand mixtures</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Categories</th><td><ul><li><a href="/mesh/immunosuppressive-agents">Immunosuppressive Agents</a></li>
<li><a href="/mesh/angiogenesis-inhibitors">Angiogenesis Inhibitors</a></li>
<li><a href="/mesh/leprostatic-agents">Leprostatic Agents</a></li>
<li><a href="/mesh/teratogens">Teratogens</a></li></ul></td></tr><tr><th>CAS number</th><td>50-35-1</td></tr><tr><th>Weight</th><td>Average: 258.2295<br>Monoisotopic: 258.064056818</td></tr><tr><th>Chemical Formula</th><td>C<sub>13</sub>H<sub>10</sub>N<sub>2</sub>O<sub>4</sub></td></tr><tr><th>InChI Key</th><td>UEJJHQNACJXSKW-UHFFFAOYSA-N</td></tr><tr><th>InChI</th><td><div class="wrap">InChI=1S/C13H10N2O4/c16-10-6-5-9(11(17)14-10)15-12(18)7-3-1-2-4-8(7)13(15)19/h1-4,9H,5-6H2,(H,14,16,17)</div></td></tr><tr><th>IUPAC Name</th><td><div class="wrap">2-(2,6-dioxopiperidin-3-yl)-2,3-dihydro-1H-isoindole-1,3-dione</div></td></tr><tr><th>SMILES</th><td><div class="wrap">O=C1N(C2CCC(=O)NC2=O)C(=O)C2=CC=CC=C12</div></td></tr><tr><th>Mass Spec</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="taxonomy"><th class="divider" colspan="2">Taxonomy</th></tr><tr><th>Kingdom</th><td>Organic Compounds</td></tr><tr><th>Superclass</th><td>Heterocyclic Compounds</td></tr><tr><th>Class</th><td>Isoindoles and Derivatives</td></tr><tr><th>Subclass</th><td>Isoindolines</td></tr><tr><th>Direct parent</th><td>Isoindolones</td></tr><tr><th>Alternative parents</th><td>Isoindoles; Piperidinediones; Delta Lactams; Aminopiperidines; N-substituted Carboxylic Acid Imides; Benzene and Substituted Derivatives; N-unsubstituted Carboxylic Acid Imides; Tertiary Carboxylic Acid Amides; Secondary Carboxylic Acid Amides; Tertiary Amines; Carboxylic Acids; Polyamines; Isoindlines</td></tr><tr><th>Substituents</th><td>piperidinedione; piperidinone; 3-aminopiperidine; delta-lactam; benzene; piperidine; carboxylic acid imide, n-substituted; tertiary carboxylic acid amide; carboxylic acid imide, n-unsubstituted; carboxylic acid imide; lactam; tertiary amine; carboxamide group; secondary carboxylic acid amide; carboxylic acid derivative; polyamine; carboxylic acid; amine; organonitrogen compound</td></tr><tr><th>Classification description</th><td>This compound belongs to the isoindolones. These are aromatic polycyclic compounds that an isolindole bearing a ketone.</td></tr><tr id="pharmacology"><th class="divider" colspan="2">Pharmacology</th></tr><tr><th>Indication</th><td>For the acute treatment of the cutaneous manifestations of moderate to severe erythema nodosum leprosum (ENL). Also for use as maintenance therapy for prevention and suppression of the cutaneous manifestations of ENL recurrence.</td></tr><tr><th>Pharmacodynamics</th><td>Thalidomide is an immunomodulatory agent with a spectrum of activity that is not fully characterized. Thalidomide is racemic &#8212; it contains both left and right handed isomers in equal amounts: one enantiomer is effective against morning sickness, and the other is teratogenic. The enantiomers are converted to each other in vivo. That is, if a human is given D-thalidomide or L-thalidomide, both isomers can be found in the serum. Hence, administering only one enantiomer will not prevent the teratogenic effect in humans.</td></tr><tr><th>Mechanism of action</th><td>In patients with erythema nodosum leprosum (ENL) the mechanism of action is not fully understood. Available data from in vitro studies and preliminary clinical trials suggest that the immunologic effects of this compound can vary substantially under different conditions, but may be related to suppression of excessive tumor necrosis factor-alpha (TNF-a) production and down-modulation of selected cell surface adhesion molecules involved in leukocyte migration. For example, administration of thalidomide has been reported to decrease circulating levels of TNF-a in patients with ENL, however, it has also been shown to increase plasma TNF-a levels in HIV-seropositive patients. As a cancer treatment, the drug may act as a VEGF inhibitor.</td></tr><tr><th>Absorption</th><td>The absolute bioavailability has not yet been characterized in human subjects due to its poor aqueous solubility. In studies of both healthy volunteers and subjects with Hansen&#8217;s disease, the mean time to peak plasma concentrations (Tmax) ranged from 2.9 to 5.7 hours indicating that thalidomide is slowly absorbed from the gastrointestinal tract.</td></tr><tr><th>Volume of distribution</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Protein binding</th><td>55% and 66% for the (+)R and (&#8722;)S enantiomers, respectively.</td></tr><tr><th>Metabolism</th><td class="data-table-container"><p>Thalidomide itself does not appear to be hepatically metabolized to any large extent, but appears to undergo non-enzymatic hydrolysis in plasma to multiple metabolites. Thalidomide may be metabolized hepatically by enzymes of the cytochrome P450 enzyme system. The end product of metabolism, phthalic acid, is excreted as a glycine conjugate.</p><table class="table-standard table-condensed" id="experimental-properties"><thead><tr><th>Substrate</th><th>Enzymes</th><th colspan="2">Product</th></tr></thead><tbody><tr><td>Thalidomide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00033">cis, trans-5'-Hydroxythalidomide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/33">Details</a></td></tr><tr><td>Thalidomide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li></ul></td><td><a href="/metabolites/DBMET00034">5-Hydroxythalidomide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/34">Details</a></td></tr><tr><td>Thalidomide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li>
<li><a href="/biodb/bio_entities/BE0002433" target="_blank">Cytochrome P450 1A2</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003533" target="_blank">Cytochrome P450 2E1</a></li></ul></td><td><a href="/metabolites/DBMET00035">Thalidomide arene oxide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/35">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00035">Thalidomide arene oxide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET00034">5-Hydroxythalidomide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1215">Details</a></td></tr><tr><td><a href="/metabolites/DBMET00034">5-Hydroxythalidomide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><ul><li><a href="/biodb/bio_entities/BE0002793" target="_blank">Cytochrome P450 2C9</a></li>
<li><a href="/biodb/bio_entities/BE0003536" target="_blank">Cytochrome P450 2C19</a></li>
<li><a href="/biodb/bio_entities/BE0003543" target="_blank">Cytochrome P450 1A1</a></li></ul></td><td><a href="/metabolites/DBMET01114">5,6-dihydroxythalidomide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1216">Details</a></td></tr><tr><td>Thalidomide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01115">4-phthalimidoglutaramic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1217">Details</a></td></tr><tr><td>Thalidomide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01116">2-phthalimidoglutaramic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1218">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01116">2-phthalimidoglutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01117">2-phthalimidoglutaric acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1219">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01115">4-phthalimidoglutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01117">2-phthalimidoglutaric acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1220">Details</a></td></tr><tr><td>Thalidomide</td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01118">alpha-(o-carboxybenzamido)glutarimide</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1221">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01115">4-phthalimidoglutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01119">4-(o-carboxybenzamido)glutaramic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1222">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01116">2-phthalimidoglutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01120">2-(o-carboxybenzamido)glutaramic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1223">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01118">alpha-(o-carboxybenzamido)glutarimide</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01120">2-(o-carboxybenzamido)glutaramic acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1224">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01119">4-(o-carboxybenzamido)glutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01121">2-(o-carboxybenzamido)glutaric acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1225">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01119">4-(o-carboxybenzamido)glutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01121">2-(o-carboxybenzamido)glutaric acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1226">Details</a></td></tr><tr><td><a href="/metabolites/DBMET01120">2-(o-carboxybenzamido)glutaramic acid</a></td><td class="enzymes"><div class="arrow"><span class="glyphicon glyphicon-arrow-right"> </span></div><span class="wishart wishart-not-available">Not Available</span></td><td><a href="/metabolites/DBMET01121">2-(o-carboxybenzamido)glutaric acid</a></td><td class="actions"><a class="btn btn-info btn-sm" href="/reactions/1227">Details</a></td></tr></tbody></table></td></tr><tr><th>Route of elimination</th><td>Thalidomide itself has less than 0.7% of the dose excreted in the urine as unchanged drug.</td></tr><tr><th>Half life</th><td>The mean half-life of elimination ranges from approximately 5 to 7 hours following a single dose and is not altered upon multiple dosing.</td></tr><tr><th>Clearance</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>Toxicity</th><td>The R-configuration and the S-configuration are more toxic individually than the racemic mixture. The LD<sub>50</sub> could not be established in mice for racemic thalidomide, whereas LD<sub>50</sub> values for the R and S configurations are reported to be 0.4 to 0.7 g/kg and 0.5 to 1.5 g/kg, respectively.</td></tr><tr><th>Affected organisms</th><td><ul><li>Humans and other mammals</li></ul></td></tr><tr><th>Pathways</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Effects</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr><th>SNP Mediated Adverse Drug Reactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="admet"><th class="divider" colspan="2">ADMET</th></tr><tr><th>Predicted ADMET features</th><td class="data-table-container"><table class="table table-condensed table-striped" id="predicted-admet">
  <thead>
    <tr>
      <th>Property</th>
      <th>Value</th>
      <th>Probability</th>
    </tr>
  </thead>
  <tbody>
      <tr>
        <td>Human Intestinal Absorption</td>
        <td>
              +
        </td>
        <td>0.9775</td>
      </tr>
      <tr>
        <td>Blood Brain Barrier</td>
        <td>
              +
        </td>
        <td>0.9382</td>
      </tr>
      <tr>
        <td>Caco-2 permeable</td>
        <td>
              -
        </td>
        <td>0.5651</td>
      </tr>
      <tr>
        <td>P-glycoprotein substrate</td>
        <td>
            Substrate
        </td>
        <td>0.5301</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor I</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.5115</td>
      </tr>
      <tr>
        <td>P-glycoprotein inhibitor II</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8951</td>
      </tr>
      <tr>
        <td>Renal organic cation transporter</td>
        <td>
            Non-inhibitor
        </td>
        <td>0.8179</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-substrate</td>
        <td>0.7904</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-substrate</td>
        <td>0.9116</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Substrate</td>
        <td>0.5309</td>
      </tr>
      <tr>
        <td>CYP450 1A2 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9045</td>
      </tr>
      <tr>
        <td>CYP450 2C9 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9071</td>
      </tr>
      <tr>
        <td>CYP450 2D6 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9231</td>
      </tr>
      <tr>
        <td>CYP450 2C19 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.9025</td>
      </tr>
      <tr>
        <td>CYP450 3A4 substrate</td>
        <td>Non-inhibitor</td>
        <td>0.8309</td>
      </tr>
      <tr>
        <td>CYP450 inhibitory promiscuity</td>
        <td>Low CYP Inhibitory Promiscuity</td>
        <td>0.8682</td>
      </tr>
      <tr>
        <td>Ames test</td>
        <td>
          Non AMES toxic 
        </td>
        <td>
            0.9133
        </td>
      </tr>
      <tr>
        <td>Carcinogenicity</td>
        <td>
          Non-carcinogens 
        </td>
        <td>
            0.9378
        </td>
      </tr>
      <tr>
        <td>Biodegradation</td>
        <td>
          Not ready biodegradable 
        </td>
        <td>
            0.8838
        </td>
      </tr>
      <tr>
        <td>Rat acute toxicity</td>
        <td>
          3.3039 
            LD50, mol/kg
        </td>
        <td>
            <span class="wishart wishart-not-available">Not applicable</span>
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor I)</td>
        <td>
          Weak inhibitor 
        </td>
        <td>
            0.9769
        </td>
      </tr>
      <tr>
        <td>hERG inhibition (predictor II)</td>
        <td>
          Non-inhibitor 
        </td>
        <td>
            0.8735
        </td>
      </tr>
  </tbody>
</table>
</td></tr><tr id="pharmacoeconomics"><th class="divider" colspan="2">Pharmacoeconomics</th></tr><tr><th>Manufacturers</th><td><ul><li>Celgene corp</li></ul></td></tr><tr><th>Packagers</th><td><ul><li><a href="http://www.celgene.com">Celgene</a></li>
<li><a href="http://www.idtaus.com.au">IDT Australia Ltd.</a></li>
<li><a href="http://www.pennpharm.com">Penn Pharmaceutical Services Ltd.</a></li></ul></td></tr><tr><th>Dosage forms</th><td class="data-table-container"><table class="table table-condensed table-striped datatable" id="dosages"><thead><tr><th>Form</th><th>Route</th><th>Strength</th></tr></thead><tbody><tr><td>Capsule</td><td>Oral</td><td></td></tr></tbody></table></td></tr><tr id="spectra"><th class="divider" colspan="2">Spectra</th></tr><tr><th>Spectra</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr><tr id="interactions"><th class="divider" colspan="2">Interactions</th></tr><tr><th>Drug Interactions</th><td class="data-table-container"><table class="table table-condensed table-striped" id="experimental-properties"><thead><tr><th>Drug</th><th style="width: 75%"></th></tr></thead><tbody><tr><td><a href="/drugs/DB01281">Abatacept</a></td><td>Thalidomide may increase the adverse effects of Abatacept. Increased risk of serious infection. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00479">Amikacin</a></td><td>Thalidomide increases the renal toxicity of the aminoglycoside</td></tr><tr><td><a href="/drugs/DB00026">Anakinra</a></td><td>Thalidomide may increase the adverse effects of Anakinra. Increased risk of serious infection. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB01234">Dexamethasone</a></td><td>Increased risk of dermatologic adverse effects and venous thromboembolic events (VTE). Consider VTE prophylaxis during concomitant therapy and monitor for adverse dematologic effects. </td></tr><tr><td><a href="/drugs/DB00798">Gentamicin</a></td><td>Thalidomide increases the renal toxicity of the aminoglycoside</td></tr><tr><td><a href="/drugs/DB00108">Natalizumab</a></td><td>Thalidomide may increase the adverse effects of Natalizumab. Concurrent administration should be avoided due to increased risk of infection.</td></tr><tr><td><a href="/drugs/DB00955">Netilmicin</a></td><td>Thalidomide increases the renal toxicity of the aminoglycoside</td></tr><tr><td><a href="/drugs/DB06372">Rilonacept</a></td><td>Thalidomide may increase the adverse effects of Rilonacept. Increased risk of serious infection. Concomitant therapy should be avoided. </td></tr><tr><td><a href="/drugs/DB00684">Tobramycin</a></td><td>Thalidomide increases the renal toxicity of the aminoglycoside</td></tr><tr><td><a href="/drugs/DB00072">Trastuzumab</a></td><td>Trastuzumab may increase the risk of neutropenia and anemia. Monitor closely for signs and symptoms of adverse events. </td></tr><tr><td><a href="/drugs/DB00427">Triprolidine</a></td><td>The CNS depressants, Triprolidine and Thalidomide, may increase adverse/toxic effects due to additivity. Monitor for increased CNS depressant effects during concomitant therapy. </td></tr></tbody></table></td></tr><tr><th>Food Interactions</th><td><span class="wishart wishart-not-available">Not Available</span></td></tr></tbody></table>